Skip to content
Open access · US-GOV via ClinicalTrials.gov Clinical trial

ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL

Authors not listed

Danielle Wallace · 2025

Abstract

Older patients with diffuse large B- cell lymphoma (DLBCL) do not have the same rates of disease control as younger patients and are at risk for toxicity. Identifying which patients might benefit from more therapy at the end of first-line treatment is important. The ability to measure small amounts of persistent lymphoma (circulating tumor DNA or ctDNA) might allow the investigators to risk stratify patients. If older patients have detectable ctDNA in the blood at the end of six cycles of polatuzumab vedotin, rituximab and dose-attentuated CHP chemotherapy, patients will receive a bispecific antibody called mosunetuzumab. The investigators hypothesize this will result in "clearing" the ctDNA from the blood and result in better disease control and outcomes for patients. The study will also measure the safety of this regimen and the impact on the function of these older patients utilizing a tool called the geriatric assessment.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
ClinicalTrials.gov
Canonical
link ↗
Fetched
2026-11-07 MST

Cite this

APA
Anonymous. (2025). ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL. <em>Danielle Wallace</em>. https://clinicaltrials.gov/study/NCT06828991
Vancouver
Anonymous. ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL. Danielle Wallace. 2025.
BibTeX
@misc{anon2025ctDNAG, title = {ctDNA-Guided Mosunetuzumab Consolidation Therapy in Older Patients With Untreated DLBCL}, author = {Anonymous}, journal = {Danielle Wallace}, year = {2025}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings